Evidence map›Paper›PMID 28315063›Full record

Trial reportJournal of neuro-oncology2017

The effect of regadenoson on the integrity of the human blood-brain barrier, a pilot study.

Sadhana Jackson, Richard T George, Martin A Lodge, Anna Piotrowski, Richard L Wahl, Sachin K Gujar, Stuart A Grossman

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 42 citations in OpenAlex.

  1. The effect of an adenosine AFluids and barriers of the CNS · 2018
    Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Towards updated understanding of brain metastasis.American journal of cancer research · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sadhana JacksonBrain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA.
Richard T GeorgeHeart and Vascular Institute, Johns Hopkins University, 600 N. Wolfe Street, Sheikh Zayed Tower, Baltimore, MD, 21287, USA.
Martin A LodgeNuclear Medicine, Russell H. Morgan Dept. of Radiology and Radiological Sciences, Johns Hopkins University, 601 Caroline St, Baltimore, MD, 21231, USA.
Anna PiotrowskiBrain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA.
Richard L WahlNuclear Medicine, Russell H. Morgan Dept. of Radiology and Radiological Sciences, Johns Hopkins University, 601 Caroline St, Baltimore, MD, 21231, USA.
Sachin K GujarRadiology and Radiological Science, Johns Hopkins University, 600 N. Wolfe Street, Sheikh Zayed Tower, Baltimore, MD, 21287, USA.
Stuart A GrossmanBrain Cancer Program, Johns Hopkins University, David H. Koch Cancer Research Building II, 1550 Orleans Street, Room 1M16, Baltimore, MD, 21287, USA. grossman@jhmi.edu.
Johns Hopkins University · US

Funding

Clinical Pharmacology Training ProgramT32GM066691 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI Matthew Michael Ippolito · 2003 to 2026
$6.4M
Modulating BBB Permeability in Malignant GliomaZIABC011686 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JACKSON, SADHANA · 2016 to 2019
$1.6M
Brain Interstitium Temozolomide Concentration Pre and Post RegadenosonZIABC011685 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JACKSON, SADHANA · 2016 to 2018
$411k
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011685Intramural NIH HHS ZIA BC011686NIGMS NIH HHS T32 GM066691
6 · The paper itself

Abstract

Regadenoson is an FDA approved adenosine receptor agonist which increases blood-brain barrier (BBB) permeability in rodents. Regadenoson is used clinically for pharmacologic cardiac stress testing using SPECT or CT imaging agents that do not cross an intact BBB. This study was conducted to determine if standard doses of regadenoson transiently disrupt the human BBB allowing higher concentrations of systemically administered imaging agents to enter the brain. Patients without known intracranial disease undergoing clinically indicated pharmacologic cardiac stress tests were eligible for this study. They received regadenoson (0.4 mg) followed by brain imaging with either

Indexed as

Adenosine A2 Receptor AgonistsAgedBlood-Brain BarrierBrainCardiac-Gated Single-Photon Emission Computer-Assisted TomographyContrast MediaFemaleHumansMaleMiddle AgedNeuroimagingPilot ProjectsPurinesPyrazolesRadiopharmaceuticalsTechnetium Tc 99m MedronateAdenosine A2 Receptor AgonistsContrast MediaPurinesPyrazolesRadiopharmaceuticalsregadenosonTechnetium Tc 99m Medronate99mTc-sestamibiBlood–brain barrier permeabilityDrug entryRegadenosonVisipaque

Identifiers

PMID28315063
PMCPMC6341476
OpenAlexW2596856888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.